PACE

Pathways to Antimicrobial Clinical Efficacy. Accelerating and strengthening the pre-clinical AMR pipeline.
@LifeArc1 | @InnovateUK | @MedDiscCat

[PACE @PACE_AMR]

@genevaUSA PACE will support The Geneva Foundation and Triari Pharmaceuticals to generate the critical data packages needed to position them for onward funding and investment .

Find out more about the project by visiting our Portfolio page: https://t.co/3Qec5TKEFu

[PACE @PACE_AMR]

We are delighted to welcome Dr Dan Zurawski of @genevaUSA and Triari Pharmaceuticals into the #PACEPortfolio. Dan and his team are developing human monoclonal antibodies targeting 𝘈𝘤𝘪𝘯𝘦𝘵𝘰𝘣𝘢𝘤𝘵𝘦𝘳 𝘣𝘢𝘶𝘮𝘢𝘯𝘯𝘪𝘪.

[PACE @PACE_AMR]

@genevaUSA PACE will support The Geneva Foundation and Triari Pharmaceuticals to generate the critical data packages needed to position them for onward funding and investment .

Find out more about the project by visiting our Portfolio page: https://t.co/3Qec5TKEFu

[PACE @PACE_AMR]

We are at ESCMID Global 2025 in Vienna, Austria! R&D Advisors, Lisa Dawson and Jon Gibson, are representing PACE, so please do talk to them and find out what we are doing to support the AMR R&D community.

#ESCMIDGlobal2025

[PACE @PACE_AMR]

🔵 Our Programme Director, Dr Beverley Isherwood was recently interviewed by Helen Albert for Inside Precision Medicine. Read about how PACE is supporting early-stage innovation to help tackle AMR.

https://t.co/KuaLdelmvD

#AMR
@MedDiscCat | @innovateuk | @lifearc1

[PACE @PACE_AMR]

@immunethep (2/2) Through access to expertise and enabling capabilities, we will support Immunethep to progress their asset towards the clinic. Find out more about the project by visiting our Portfolio page: https://t.co/3Qec5TKEFu

[PACE @PACE_AMR]

Congratulations to @immunethep!

We are delighted to announce that Immunethep has joined the PACE portfolio. Immunethep is advancing monoclonal antibodies to restore the ability to control bacterial infection. (1/2)

[PACE @PACE_AMR]

ApconiX, BioAscent, Domainex, Absolute Antibody, Pharmidex, IHMA, Abingdon Health plc, Evotec, CPI, Boyds, TTP plc, Charles River Laboratories, Concept Life Sciences, Fios Genomics, APIS Assay Technologies Ltd, Biofortuna, BBI Solutions

(2/2)

[PACE @PACE_AMR]

Meet our PACE Delivery Partners! Innovators require support to accelerate antimicrobial & diagnostic discovery. Our Delivery Partner Network (DPN) connects providers with innovators to help with outsourced work & advice for PACE-funded projects.

🔗: https://t.co/J1KMPN8VLI
(1/2)

[PACE @PACE_AMR]

🔵 This week, #PACE is at the 9th #AMRConference in Switzerland, connecting with global innovators and hearing from great speakers. If you're attending visit us at exhibition booth 1 to learn about our work tackling #AMR. Thanks to organisers @AllianceBEAM and bamconn GmbH.

[PACE @PACE_AMR]

@IneosOxford By supporting organisations such as IOI, we aim to maximise the success of leading antimicrobial innovations, accelerating project development with greater speed and confidence.

Find out more about the project by visiting our Portfolio page: https://t.co/3Qec5TKEFu

[PACE @PACE_AMR]

It is a pleasure to welcome @IneosOxford (IOI) for #AntimicrobialResearch into the #PACEPortfolio. IOI is optimising a new class of broad-spectrum cell wall transpeptidase inhibitors.

[PACE @PACE_AMR]

@OxDrugDes We look forward to supporting Oxford Drug Design to advance their asset by offering guidance, mentorship, and access to enabling tools and technologies.

Find out more about the project by visiting our Portfolio page: https://t.co/3Qec5TKEFu

#AMR

[PACE @PACE_AMR]

We are thrilled to welcome @OxDrugDes as the latest member of the #PACEPortfolio. Oxford Drug Design is progressing small molecule, locally-acting enzyme inhibitors for oral therapy of urinary tract infections.

[PACE @PACE_AMR]

We are delighted to be attending next week’s #AMRConference: Novel Antimicrobials and AMR Diagnostics. We have a space in the exhibition area (booth number 1), so please stop by to find out how PACE is supporting early-stage innovation to tackle AMR.

🔗 https://t.co/01ve3CAH7l

[PACE @PACE_AMR]

Through access to mentors, advisors and enabling capabilities, PACE will support PhalconBio to progress its innovative technology towards the clinic.

Find out more about the project by visiting our Portfolio page: https://t.co/3Qec5TKEFu

[PACE @PACE_AMR]

Congratulations to PhalconBio!

We are delighted to announce that PhalconBio has joined the #PACEPortfolio. PhalconBio is advancing dual-action, inhalable phage treatments for bronchiectasis-associated 𝘗𝘴𝘦𝘶𝘥𝘰𝘮𝘰𝘯𝘢𝘴 𝘢𝘦𝘳𝘶𝘨𝘪𝘯𝘰𝘴𝘢 infections.

[PACE @PACE_AMR]

@jlugiessen @INFEX_TX We look forward to working together to move their project closer to the clinic, and ultimately bring new antibiotics to tackle the major global health challenge that is #AMR.

Find out more about the project by visiting our Portfolio page: https://t.co/3Qec5TKEFu

[PACE @PACE_AMR]

It’s a pleasure to welcome Professor Till Schäberle of @jlugiessen University Giessen in partnership with @INFEX_TX, to the PACE portfolio. As collaborators they are optimising a membrane-targeting bicyclic heptapeptide for treatment of Gram-negative infections.

[PACE @PACE_AMR]

🔵 PACE at #BioInfect2025 in Liverpool. Dr. Beverley Isherwood and Dr. Phil Packer have been speaking about our work supporting early-stage projects, our enabling collaborations and our role in funding #AMR R&D.
@Bionow